Canaccord Drops Antibe’s Price Target To $0.70 Following Asset Sale
Antibe Therapeutics Inc. (TSX: ATE) recently reported their full-year 2022 results, wherein the company reported it ended the year with
Read more
Antibe Therapeutics
Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot
In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study of otenaproxesul because it breached
Read more
Canaccord Slashes Antibe Therapeutics Price Target A Month After Drug Trial Paused
On August 3, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study of otenaproxesul because it breached
Read more
Antibe Therapeutics Pauses Otenaproxesul Trial After Exceeding Safety Threshold
Antibe Therapeutics Inc. (TSX: ATE) shared today that it is putting on pause the absorption, metabolism, and excretion study of
Read more
Antibe: Canaccord Raises Price Target After Q4 Results
On June 28th, Antibe Therapeutics (TSX: ATE) reported their fourth quarter and year-end financials. The company announced full-year revenue of
Read more
Antibe: Canaccord Lowers Price Target After Co-Leading $40.4 Million Financing
Wednesday, Antibe Therapeutics (TSX: ATE) announced that they closed their bought deal financing. The bought deal was for 6.7 million
Read more
Antibe Therapeutics To Raise $35.1 Million In Bought Deal
Money continues to be raised at a feverish pace in the capital markets, with Antibe Therapeutics (TSX: ATE) the latest
Read more
Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50
Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm in China. The deal includes
Read more
Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target
Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company developing a nonsteroidal anti-inflammatory drugs
Read more
Antibe Therapeutics Proposes Share Consolidation To Enable Potential Nasdaq Listing
It appears that Antibe Therapeutics (TSXV: ATE) is still mulling a share consolidation that it had previously received shareholder approval
Read more